Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease.

ABSTRACT: Over the past few decades, a series of innovative medicines have been developed in order to optimize anticoagulation therapy for atrial fibrillation (AF). As a result, a number of nonvitamin K antagonist oral anticoagulants (NOAC) that directly target the enzymatic activity of factor II and factor Xa have been successfully licensed providing a more predictable effect and better safety profile compared to conventional anticoagulants (heparins and vitamin K antagonists (VKAs)). However, comparative efficacy and safety data is limited in patients with advanced chronic kidney disease (i.e., CKD stage 4/5 and end stage renal disease) because patients with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 were actively excluded from landmark trials, thus representing a major clinic

SUBMITTER: Stoica MC 

PROVIDER: S-EPMC8147111 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature